Merck & Co. Inc. (MRK) announced the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMEA has recommended approval of ELONVA, or corifollitropin alfa injection, as a treatment in controlled ovarian stimulation or COS in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology or ART program. If approved by the European Commission, Merck would receive marketing authorization for ELONVA with unified labeling valid in all European Union Member States.
For comments and feedback: editorial@rttnews.com